Pulmonology Medical News about Rivaroxaban

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
Cardiology In Review, 06/19/09

Chen T et al. - Rivaroxaban is a novel oral direct factor Xa inhibitor. Rivaroxaban has been shown to have tolerable adverse effects and a low potential for drug-drug or drug-food interactions. It has the major advantages of once daily oral dosing and no required laboratory monitoring, giving it the potential to replace current antithrombotics in the market today.

<< Previous
Long-term results of percutaneous management of malperfusion in...

Next >>
Incidence of seropositivity to bordetella pertussis and...

A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting
PharmacoEconomics, 10/12/09 Relevance Score: 89%

The new oral anticoagulants
Blood, 11/13/09 Relevance Score: 80%